Anne McGeorge has almost 40 years of experience providing strategic guidance and operational oversight to health care organizations. Ms. McGeorge currently serves as the Chairman of the Board of Directors, as well as a member of the Compensation Committee, at The Oncology Institute, Inc. She also serves on the Board of Directors, as well as the Audit Committee Chair of two private companies, CitiusTech, a health care technology company, and Nimbus Therapeutics, LLC, a biotech company. She is also on the board of CLEAR Insurance, a Cayman based captive insurance company, the National Marrow Donor Program (aka Be The Match), a 501(c)(3) organization, the William and Mary Raymond Mason School of Business Foundation, and is on the advisory board at FCA Healthcare Innovations, a venture capital company. Additionally, Ms. McGeorge previously served on the Board of Directors of SOC Telemed, Inc. from October 2020 until it was acquired by Patient Square Capital, Inc. Ms. McGeorge is also on the adjunct faculty at the University of North Carolina at Chapel Hill. Prior to her retirement in July 2017, Ms. McGeorge worked at Grant Thornton LLP where she routinely advised clients on audit, tax, and financial matters relating to the healthcare industry. During her time at Grant Thornton LLP, Ms. McGeorge was Managing Partner of Grant Thornton LLP’s Health Care Industry Practice from January 2006 to July 2017, as well as Global Managing Partner for Grant Thornton International’s Health Care Industry Practice from August 2015 to July 2017. Ms. McGeorge was formerly a partner at Deloitte LLP from 2002 to 2005 and at Arthur Andersen LLP from 1997 to 2002. Ms. McGeorge received a B.B.A., Business, Accounting from the College of William and Mary, and an M.S., Accounting/Taxation from the University of Virginia. LinkedIn Profile
What is Anne McGeorge's net worth?
The estimated net worth of Anne McGeorge is at least $135.61 thousand as of August 10th, 2026. Ms. McGeorge owns 1,250 shares of Dianthus Therapeutics stock worth more than $135,613 as of August 12th. This net worth approximation does not reflect any other assets that Ms. McGeorge may own. Learn More about Anne McGeorge's net worth.
How do I contact Anne McGeorge?
Has Anne McGeorge been buying or selling shares of Dianthus Therapeutics?
During the last ninety days, Anne McGeorge has sold $844,827.50 of Dianthus Therapeutics stock. Most recently, Anne Mcgeorge sold 7,750 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a transaction totalling $844,827.50. Following the completion of the sale, the director now directly owns 1,250 shares of the company's stock, valued at $136,262.50. Learn More on Anne McGeorge's trading history.
Who are Dianthus Therapeutics' active insiders?
Are insiders buying or selling shares of Dianthus Therapeutics?
During the last twelve months, insiders at the sold shares 17 times. They sold a total of 843,865 shares worth more than $64,836,552.05. The most recent insider tranaction occured on August, 10th when Director Anne Mcgeorge sold 7,750 shares worth more than $844,827.50. Insiders at Dianthus Therapeutics own 3.0% of the company.
Learn More about insider trades at Dianthus Therapeutics. Information on this page was last updated on 8/10/2026.